CorMedix vs Liquidia
CRMD and LQDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRMD and LQDA compare
Liquidia is the larger company, worth 14 times as much as CorMedix ($5.1B against $363M).
Liquidia grew revenue faster over the last twelve months (798% versus 92.5% for CorMedix).
CorMedix keeps more of each dollar of sales as profit, with a net margin of 15.5% compared with −15.1% at Liquidia.
CorMedix scores higher on the StockData Score (15 against 10 for Liquidia), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRMD | LQDA |
|---|---|---|
| Size and price | ||
| Market cap | $363M | $5.1B |
| Share price | $4.66 | $57.41 |
| Change, 1 year | −59.2% | 103% |
| Change, 5 years | −9.2% | 1248% |
| Beta (5Y) | 1.37 | 0.97 |
| Employees | 191 | 216 |
| StockData Score | ||
| Total score | 15 (better) | 10 |
| Valuation score | 3 (better) | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 4 (better) | 2 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.9× (better) | 8.3× |
| P/B | 0.8× | – |
| EV/EBITDA | 0.1× | – |
| P/FCF | 1.2× (better) | 17.6× |
| FCF yield | 84.8% (better) | 5.7% |
| Fair value | $34.62 | – |
| Margin of safety | 86.5% | – |
| Growth | ||
| Revenue growth (TTM) | 92.5% | 798% (better) |
| Revenue growth, 5Y average | 320% (better) | 192% |
| Net income growth (TTM) | −60.7% | – |
| Profitability | ||
| Gross margin | 77.5% | – |
| Operating margin | 38.6% (better) | −15.6% |
| Net margin | 15.5% (better) | −15.1% |
| FCF margin | 74.6% (better) | 46.8% |
| Return on equity | 15.3% | – |
| Return on invested capital | 37.4% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 2.43 (better) | 1.02 |
| Altman Z-score | 1.69 | 3.31 (better) |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | −3.1% | – |
| Shareholder yield | −3.1% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 56.5% | 81.1% |
| Held by insiders | 3.2% | 19.5% |
| Insider net buying, 12 months | −$2.0M (better) | −$227M |
| Short interest, % of float | 18.8% | 24.3% |
Go deeper
- CRMD stock overview
- CRMD income statement
- CRMD valuation and score
- LQDA stock overview
- LQDA income statement
- LQDA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.